系统性硬化症相关间质性肺病试验中呼吸患者报告结局工具的表现:我们是否在第一关就失败了?
综述系统评估了系统性硬化症相关间质性肺病(SSc-ILD)随机对照试验中呼吸特异性患者报告结局(PRO)工具的使用、有效性和表现。检索识别出10种工具,其中4种为单条目工具,仅2种有ILD患者参与开发。
要点
- SSc-ILD试验中使用的呼吸特异性PRO工具内容效度未经证实,缺乏共识。
- 仅2种工具开发时有ILD患者参与,多数工具测量学特性证据有限。
- 未来应依据COSMIN指南优先评估现有ILD特异性工具的内容效度和测量学特性。
核心结论
- SSc-ILD随机对照试验中呼吸特异性PRO工具的使用缺乏共识,现有工具在该人群中内容效度未经证实且其他测量学特性证据有限。
研究设计与样本
- 本综述采用COSMIN框架和监管指南,系统检索并评估SSc-ILD随机对照试验中使用的呼吸特异性PRO工具的纳入情况、有效性和表现。
主要发现
- 检索识别出10种用于SSc-ILD随机对照试验的呼吸特异性PRO工具,其中4种为单条目工具,2种开发时有任何ILD患者参与。
- 现有工具的测量学特性证据主要来自随机对照试验数据的事后分析或横断面研究。
关键数值与推荐
- 用力肺活量(FVC)已被认可作为评估SSc-ILD新疗法疗效的随机对照试验的主要结局指标。
- 监管机构认为患者「感觉」和「功能」信息对上市许可至关重要,仅PRO工具可提供此信息。
临床怎么用
- 临床解读SSc-ILD试验中呼吸特异性PRO工具结果时需谨慎,因其内容效度未经证实且测量学特性证据有限。
- 未来研究应依据COSMIN指南优先评估现有ILD特异性工具的内容效度和测量学特性。
局限性
- 现有工具的测量学特性证据主要来自事后分析或横断面研究,方法学异质性大。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Interstitial lung disease (ILD) affects up to half of individuals with systemic sclerosis (SSc), within which it is a major cause of disease-related morbidity and a leading cause of mortality. Forced vital capacity (FVC) has been endorsed as a primary outcome measure for randomised controlled trials (RCT) assessing the efficacy of novel treatments for SSc-ILD. The FVC is considered a suitable surrogate biomarker, although does not directly capture information on how patients 'feel' and 'function', which regulators consider essential for marketing authorisation. Only patient-reported outcome (PRO) instruments can provide this insight. This review aims to systematically examine the inclusion, validity and performance of respiratory-specific PRO instruments used in SSc-ILD RCTs, using the COnsensus based Standards for the selection of health Measurement INstruments (COSMIN) framework and regulatory guidance. Our search identified 10 respiratory-specific PRO instruments used in SSc-ILD RCTs. Of these, 4 are single-item instruments and 2 were developed with any ILD patient input. Seventeen studies assessing the measurement properties of respiratory-specific PRO instruments within an SSc-ILD population were identified, with varying methodologies. The findings of this review highlight the lack of consensus for the use of respiratory-specific PRO instrument use in SSc-ILD RCTs. Identified instruments have unproven content validity within this population and limited evidence for other measurement properties, primarily derived from post hoc analyses of RCT data or cross-sectional studies. Future work should prioritise assessing the content validity and measurement properties of existing ILD specific instruments according to COSMIN guidance.
引用
- Wells M, Buckley K, Bernstein EJ, et al. Performance of respiratory patient reported outcome instruments in systemic sclerosis associated interstitial lung disease trials: Are we falling at the first hurdle? Semin Arthritis Rheum. 2026. PMID: 42743702. doi:10.1016/j.semarthrit.2026.153068
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。